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ABSTRACT
KRAS mutations occur in ~90% of all pancreatic cancers and in ~20% of all human cancers, but no effective therapies targeting KRAS have been developed. We proposed a functional genomic screen to identify gene targets that, when inhibited, cooperate with MEK inhibitors (which block signaling through the MAPK pathway, a key KRAS effector) to kill KRAS mutant pancreatic cancer cells in order to develop novel therapeutic combinations for these cancers. Our efforts identified several components within the MAPK pathway that can lead to feedback reactivation of MAPK signaling despite the presence of MEK inhibitors, creating a key vulnerability of MEK inhibitors that can lead to resistance. Importantly, we found that ERK inhibitors (which block downstream of MEK inhibitors) could overcome MAPK reactivation and produced enhanced efficacy. Our efforts also identified multiple members of a metabolic and autophagy-regulating pathway, suggesting that autophagy inhibitors (currently in clinical trials for pancreatic cancer) in combination with MAPK inhibitors may be a promising approach. We expect these data to drive new clinical trials for pancreatic cancer patients. 
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OVERALL PROJECT SUMMARY:
Summary of Progress by Specific Task
Task 1:
Following approval of the appropriate animal protocol (task 1a), a primary in vivo shRNA-drug screen in mouse PDAC xenografts was attempted using 6 PDAC cell lines (tasks 1b,c).
Unfortunately, technical limitations restricted our ability to obtain workable data from the pooled shRNA-drug screen in xenografts. The major factor that limited our ability to successfully execute the screen in xenografts was the efficiency with which these PDAC cell lines formed subcutaneous xenograft tumors. In order to achieve the desired coverage of at least 1000 cells per shRNA in the Despite the technical difficulties experienced with Task 1, an shRNA "mini-pool" was successfully constructed (task 2a) for prioritization and validation of candidate targets based on top hits identified through parallel control screens conducted in Task 1 using standard methods.
However, the same technical issues related to the required efficiency of tumor formation for adequate shRNA representation also limited our attempts to successfully execute the secondary orthotopic shRNA-drug screen (tasks 2b,c). Again, despite efforts to troubleshoot the process, including parallel control validation experiments performed using standard methods, we were not able to establish suitable in vivo screening conditions. However, through our parallel control experimental efforts we were able to validate and prioritize two top-tier hits for further characterization and in vivo efficacy evaluation in mice in Task 3.
Task 3:
While the technical difficulties experienced in performing Tasks 1 and 2 created significant delays in the project, we were ultimately able to initiate in vivo testing of potential therapeutic strategies in a mouse PDAC model, as originally proposed, based on hits prioritized in Task 2.
Although the data are not mature, a MEK inhibitor and ERK inhibitor (based on prioritized hits) are currently being evaluated for efficacy (task 3a) and pharmacodynamic effect (task 3b), with a particular focus on the ability to achieve robust and sustained suppression of MAPK signaling (as described in Summary of Findings and Potential Impact below). For pharmacodynamic experiments, as originally proposed, both a short (3 day) and longer (4 week) timepoint will be assessed to evaluate the degree of MAPK suppression achieved upon initiation of therapy and the ability to produce sustained pathway suppression and to prevent feedback reactivation of the pathway during prolonged therapy. Analogous studies using inhibitors of key metabolic pathways (based on additional prioritized hits) in combination with a MEK inhibitor are planned for initiation in the near future.
Summary of Findings and Potential Impact
Interestingly, all three RAF family genes were among the top five hits identified through our screening efforts. This finding is somewhat surprising since RAF kinases act upstream of MEK in the MAPK pathway, and mediate MEK phosphorylation and activation. Thus, it might be expected that MEK inhibitors would not be affected by RAF kinase activity, since they block the kinase cascade at a point downstream of RAF. Furthermore, the initial expectation would be that this approach would Importantly, however, we found that ERK inhibitors, which inhibit downstream of MEK, were far less susceptible to feedback reactivation of the MAPK pathway and were able to sustain prolonged suppression of MAPK signaling (Figure 1) . As many ERK inhibitors actually cause an increase in P-ERK levels (4, 5) , the ability of ERK inhibitors to promote sustained MAPK pathway inhibition is best evidenced by maintained suppression of the downstream ERK target P-RSK. Consistent with these findings, we observed that following prolonged exposure of KRAS mutant PDAC cells to MEK inhibitors, the potency with which MEK inhibitors could suppress MAPK signaling was markedly reduced (Figure 2 ). Cells were pre-treated for 4 days with 100nM trametinib and then treated for 2 hours with vehicle or with various concentrations of MEK or ERK inhibitors. After 4 days of MEK inhibitor pre-treatment, the ability of trametinib or selumetinib to suppress P-ERK and P-RSK was reduced by ~10 to 30-fold, suggesting that MEK inhibitors may lose efficacy in KRAS mutant PDAC cells following prolonged exposure. Conversely, the potency with which the ERK inhibitor VX-11e was able to suppress MAPK signaling was unaffected by MEK inhibitor pre-treatment ( Figure 3 ).
Collectively, these results suggest that feedback signaling changes occurring after prolonged MEK inhibitor treatment can lead to MAPK reactivation despite the continued presence of drug, but that ERK inhibitors are able to promote sustained MAPK pathway suppression despite these same feedback signaling changes.
Importantly, the ability of ERK inhibitors to maintain continued suppression of MAPK signaling translated into an improved ability to suppress KRAS mutant cell lines in long-term growth assays, compared to MEK inhibitors (Figure 3) . While the earlier generation MEK inhibitor selumetinib delayed cell growth relative to vehicle control, rapid outgrowth of cells was observed by as little as 1-2 weeks, consistent with the rapid and robust reactivation of MAPK signaling observed with prolonged treatment with selumetinib ( Figure 1) . Although, trametinib showed improved ability to suppress cell growth compared to selumetinib, consistent with the lesser degree of MAPK pathway reactivation observed with trametinib, cell outgrowth was still observed by 3-4 weeks. However, consistent with the ability of ERK inhibitors to maintain prolonged MAPK pathway suppression, the ERK inhibitor VX11e was able to sustain complete suppression of cell growth and no outgrowth was observed, even by 4 weeks. Currently, the ability of ERK inhibitors to maintain effective MAPK pathway suppression compared to MEK inhibitors in PDAC tumor cells in vivo is currently ongoing, as described above for Task 3, and potential differences in the anti-tumor efficacy of these inhibitors is also being compared. 
KEY RESEARCH ACCOMPLISHMENTS:
• Identified feedback reactivation of MAPK signaling through increased RAF activity and MEK hyperactivation as a key mechanism of resistance to MEK inhibitors in KRAS mutant PDAC that likely limits the therapeutic benefit of these agents.
• Found that ERK inhibitors are an alternative strategy for MAPK pathway inhibition in KRAS mutant PDAC that are refractory to feedback reactivation of MAPK signaling and can lead to sustained pathway suppression and improved efficacy in KRAS mutant PDAC. These findings suggest that ERK inhibitors should be actively evaluated in future clinical trials as an alternative approach to MEK inhibitors for MAPK inhibition in KRAS mutant PDAC, both alone and in combination with other targeted agents. Discussion to incorporate ERK inhibitors into clinical trials for PDAC patients are currently underway.
• Identified the LKB1/AMPK and autophagy pathway as a promising clinical target for coinhibition with the MAPK pathway in KRAS mutant PDAC.
CONCLUSION:
To 
PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:
Manuscript in preparation defining the role of feedback reactivation of MAPK signaling in overcoming the effect of MEK inhibitors and outlining the potential role of ERK inhibitors as an alterative therapeutic strategy for MAPK blockade.
We expect that our continued efforts defining the role of co-targeting autophagy and MAPK signaling to produce a high impact manuscript within the next 12 months.
INVENTIONS, PATENTS, AND LICENSES:
Nothing to report
REPORTABLE OUTCOMES:
Manuscripts in preparation, as above.
OTHER ACHIEVEMENTS:
Nothing to report REFERENCES:
